Merryn Voysey to Humans
This is a "connection" page, showing publications Merryn Voysey has written about Humans.
Connection Strength
0.100
-
ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - Authors' reply. Lancet. 2021 06 12; 397(10291):2248.
Score: 0.008
-
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021 03 06; 397(10277):881-891.
Score: 0.007
-
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021 01 09; 397(10269):99-111.
Score: 0.007
-
ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply. Lancet. 2020 11 07; 396(10261):1486-1487.
Score: 0.007
-
Computing threshold antibody levels of protection in vaccine clinical trials: An assessment of methodological bias. PLoS One. 2018; 13(9):e0202517.
Score: 0.006
-
Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clin Infect Dis. 2018 06 18; 67(1):18-24.
Score: 0.006
-
Use of weighted multivariate estimates in trials of multi-serotype vaccines to simplify interpretation of treatment differences. PLoS One. 2018; 13(4):e0196200.
Score: 0.006
-
Serotype-Specific Correlates of Protection for Pneumococcal Carriage: An Analysis of Immunity in 19 Countries. Clin Infect Dis. 2018 03 05; 66(6):913-920.
Score: 0.006
-
Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. Vaccine. 2017 10 13; 35(43):5850-5857.
Score: 0.006
-
The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses : An Individual Participant Meta-analysis. JAMA Pediatr. 2017 07 01; 171(7):637-646.
Score: 0.006
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021 09; 8(9):e568-e580.
Score: 0.002
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV. 2021 08; 8(8):e474-e485.
Score: 0.002
-
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021 04 10; 397(10282):1351-1362.
Score: 0.002
-
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021 05 20; 384(20):1885-1898.
Score: 0.002
-
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nat Med. 2021 02; 27(2):279-288.
Score: 0.002
-
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med. 2021 02; 27(2):270-278.
Score: 0.002
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021 12 19; 396(10267):1979-1993.
Score: 0.002
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 08 15; 396(10249):467-478.
Score: 0.002
-
Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial. Lancet Infect Dis. 2019 02; 19(2):156-164.
Score: 0.002
-
Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review. Clin Trials. 2018 06; 15(3):278-285.
Score: 0.002
-
Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. Pediatr Infect Dis J. 2018 04; 37(4):e103-e106.
Score: 0.002
-
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. CMAJ. 2017 Oct 16; 189(41):E1276-E1285.
Score: 0.001
-
Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data meta-analysis. PLoS Med. 2017 Oct; 14(10):e1002398.
Score: 0.001
-
An Appraisal of the Clinical Features of Pediatric Enteric Fever: Systematic Review and Meta-analysis of the Age-Stratified Disease Occurrence. Clin Infect Dis. 2017 Jun 01; 64(11):1604-1611.
Score: 0.001
-
Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. Pediatr Infect Dis J. 2017 May; 36(5):e130-e135.
Score: 0.001
-
Effect of Oral Dexamethasone Without Immediate Antibiotics vs Placebo on Acute Sore Throat in Adults: A Randomized Clinical Trial. JAMA. 2017 04 18; 317(15):1535-1543.
Score: 0.001
-
Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clin Infect Dis. 2017 04 15; 64(8):1066-1073.
Score: 0.001
-
Memory B cell response to a PCV-13 booster in 3.5year old children primed with either PCV-7 or PCV-13. Vaccine. 2017 05 09; 35(20):2701-2708.
Score: 0.001
-
Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara-Vectored Ebola Vaccines at 1 Year. JAMA. 2017 03 14; 317(10):1075-1077.
Score: 0.001
-
Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine. 2016 12 07; 34(50):6350-6357.
Score: 0.001
-
External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014 Mar 19; 14:40.
Score: 0.001